Medizone International, Inc. (OTCBB: MZEI) (http://medizoneint.com)

In this one week we have seen the three most respected news organizations in this country address the issue of Hospital Acquired Infections:  the New York Times, the Wall Street Journal and National Public Radio.  They are demanding solutions, searching for solutions and THERE ARE NO SOLUTIONS OUT THERE ….

Medizone is bringing to market its solution at an opportune time.

If there were a solution out there — one of these news organizations would have reported it.

The Wall Street Journal addressed this issue on April 14, 2010:

The nation’s hospitals are losing the battle against life-threatening infections that patients can catch as a consequence of medical treatment, federal health officials said Tuesday. The Health and Human Services Department’s 2009 quality report to Congress found “very little progress” on eliminating hospital-acquired infections and called for “urgent attention” to the shortcomings.

National Public Radio April 16, 2010

In the last month National Public Radio has looked at Hospital Acquired Infections on two different occasions.  This subject is gaining tremendous media attention.  On April 16, 2010, NPR: Talk  of  the Nation/Science Friday presented:  Bacterial  Infections Defy Treatment. MRSA and C. diff. were the topic and the program discussed how hospital-acquired  infection have moved into the community in general including prisons and athletic facilities.

The radio program included:

Stuart Levy who is a professor of molecular biology, microbiology and medicine at Tufts University. He’s also the president of the Alliance for the Prudent Use of Antibiotics and the author of “The Antibiotics Paradox: How the Misuse of Antibiotics Destroys Their Curative Powers”

Maryn McKenna who is the author of “Superbug: The Fatal Menace of MRSA.” She’s also a contributing writer at the Center for Infectious Disease Research and Policy at the University of Minnesota.

Brad Spellberg who is an assistant professor of medicine at the Los Angeles Biomedical Research Center. That’s at Harbor-UCLA Medical Center. He’s also the author of “Rising Plague: The Global Threat from Deadly Bacteria and Our Dwindling Arsenal to Fight Them.”

They discussed bacteria that are resistant to every FDA-approved antibiotic.

What is incredibly significant about this program — where Medizone International is concerned is the reality that there are really no drugs on the horizon to treat this issue.

Dr. Levy noted that it is “almost looking impossible to find new antibiotics for these drugs.”

He noted gram negative bacteria are hard to treat and have many different resistances to antibiotics and that bacteria that are resistant to every FDA-approved antibiotic are being encountered.

The pharmaceutical industry is no longer producing a next generation of drugs to deal with the previously resistant bacteria.

Dr. Levy noted two reasons for this phenomena: one is economic in that long term daily prescribed drugs are more profitable. and the return on investment for a short term drug like an antibiotic does not stack up.

The second reason he gave was the FDA where standards by which trials should be conducted to show that antibiotics work are in a state of flux and designing clinical trials to meet regulatory standards for drug approval are not clear.

NPR: Fresh Air had previously covered this issue on March 23, 2010: MRSA: The Drug-Resistant ‘Superbug’ That Won’t Die.

New York Times

The  New York Times reported on the Agency for Healthcare Research and Quality Report and  noted HOSPITAL ACQUIRED INFECTIONS NEED URGENT ATTENTION.

The Report focused on Hospital Acquired Infections, noting that the, “problem of hospital-acquired infections remains as resistant to cure as the germs that contribute to an estimated 100,000 deaths a year, according to an annual government study issued Tuesday.”

Despite threats of governmental sanctions, hospitals continue to see increased rates of post-operative bloodstream infections which increased by eight percent and catheter-associated urinary tract infections which increased by four percent.

There was no change in the incidence of bloodstream infections caused by the placement of catheters in central veins. The only positive news came from a 12 percent reduction in the rate of post-operative pneumonia.

Dr. Carolyn M. Clancy, the agency’s director, pointed out that projects across the country had shown remarkable success in reducing infection rates by adhering to basic standards for hand hygiene, disinfection of patients, sterile handling of equipment and proper use of antibiotics. But at many hospitals those successes have yet to overcome an entrenched medical culture.

‘Kathleen Sebelius, the secretary of health and human services, called the trend troubling but said the new health care law would ”help turn these numbers around.” Under the law, hospitals with high rates of infections will be penalized by the government starting in the 2015 fiscal year.

The agency has been releasing its Congressionally mandated reports on health care quality and disparities since 2003.

Medizone International, Inc. is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospitals, sports training facilities, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures. Successful decontamination by AsepticSure™ to the 6 log standard or greater has been demonstrated with C.difficile, E coli, Pseudomonas aeruginous, MRSA, VRE and Bacillius subtilis.

Medizone International’s successful decontamination by AsepticSure™ to the 6 log standard or greater on hospital surfaces represents solution for Hospital Acquired Infections and MORE.

• C.difficile
• E coli
• Pseudomonas aeruginous
• MRSA
• VRE
• Bacillius subtilis

• Hospitals
• Sports training facilities
• Schools
• Critical infrastructure

Contact: Medizone International, Inc. (OTCBB: MZEI)
(See Medizone International Video)
http://www.medizoneint.com

Telephone: 415-868-0300
Fax: 415-868-2344
Address:
Post Office Box 742
Stinson Beach, CA 94970

This release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.

Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.